Bicara Therapeutics Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Bicara Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $161.76M.
- Bicara Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $332.43M.
- Bicara Therapeutics Inc. stock issued during period, value, new issues for fiscal 2025 was $29.50M, a 91.13% decline from fiscal 2024.
- Bicara Therapeutics Inc. stock issued during period, value, new issues for fiscal 2024 was $332.43M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | $161.76M 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $29.50M 10-K · filed 2026-03-30 | |
| 2024-12-31 | $332.43M 10-K · filed 2026-03-30 | |
| 2024-09-30 | $332.43M 10-Q · filed 2025-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |